Actualités

Targeted Oncology17 h
FDA Accepts NDA of New F 18 Formulation for Prostate Cancer Imaging
FDA accepts a new formulation of piflufolastat F 18, enhancing prostate cancer imaging access and efficiency, with a target ...
Targeted Oncology15 h
Roxadustat Phase 3 Trial for Anemia in Lower-Risk MDS Receives FDA Go-Ahead
Roxadustat advances as a promising oral treatment for anemia in lower-risk myelodysplastic syndromes, targeting high ...
Targeted Oncology21 h
FDA Clears Novel Combination Trial for Recurrent Glioblastoma
A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this ...
Targeted Oncology17 h
Bexmarilimab Responses in High-Risk MDS Continue to Improve
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Targeted Oncology20 h
FDA Expands Approval for Tocilizumab Biosimilar to Treat CRS
FDA expands tocilizumab-anoh's indication for treating cytokine release syndrome, enhancing treatment options for patients ...
Targeted Oncology19 h
FDA Fast Track Designation Granted for Novel BTK/LYN Dual Inhibitor in CLL/SLL
The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment ...
Targeted Oncology15 h
FDA Approves PEG Hydrogel Embolic System for Hypervascular Tumors
The FDA approves the Embrace Hydrogel Embolic System, offering a groundbreaking treatment for hypervascular tumors in ...
Targeted Oncology14 h
Monitoring Desmoid Tumor Progression with Strategic Imaging Intervals
During a live event, Tony Philip, MD, recommended tailored imaging intervals and avoiding surgery and radiation for desmoid ...
Targeted Oncology16 h
Early Relapsed DLBCL Counseling Includes CAR T and Alternative Therapy
During a live event, Matthew Lunning, DO, and participants discussed the process of determining if patients with DLBCL should ...
Targeted Oncology22 h
New 10-Year Data Show Ibrutinib's Lasting Efficacy in CLL/SLL
The RESONATE-2 trial reveals ibrutinib's long-term efficacy and safety in treating CLL/SLL, especially for high-risk patients ...
Targeted Oncology1 j
Dordaviprone Receives Accelerated FDA Approval for Diffuse Midline Glioma
FDA accelerates approval of dordaviprone, the first targeted therapy for aggressive diffuse midline glioma, offering hope for ...
Targeted Oncology1 j
Real-World Evidence Reveals CAR T Sequencing Approach in Myeloma
During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting ...